Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Thursday.

Several other brokerages have also recently issued reports on SUPN. Piper Jaffray Companies restated a “hold” rating and issued a $44.00 price target on shares of Supernus Pharmaceuticals in a research report on Thursday, August 9th. Cantor Fitzgerald set a $57.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Mizuho initiated coverage on shares of Supernus Pharmaceuticals in a research report on Monday, September 17th. They set a “buy” rating and a $61.00 price objective for the company. B. Riley decreased their price objective on shares of Supernus Pharmaceuticals from $68.00 to $65.00 and set a “buy” rating for the company in a research report on Monday, November 12th. Finally, Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 8th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Supernus Pharmaceuticals has an average rating of “Buy” and an average target price of $56.89.

NASDAQ SUPN traded down $5.47 on Thursday, hitting $40.54. The company’s stock had a trading volume of 2,278,263 shares, compared to its average volume of 706,231. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.65 and a current ratio of 2.82. Supernus Pharmaceuticals has a 1-year low of $34.90 and a 1-year high of $61.25. The stock has a market cap of $2.40 billion, a P/E ratio of 32.17, a price-to-earnings-growth ratio of 1.45 and a beta of 0.93.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.09. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 30.30%. The firm had revenue of $102.99 million during the quarter, compared to analysts’ expectations of $100.75 million. During the same period in the prior year, the company posted $0.29 EPS. The company’s revenue was up 28.1% on a year-over-year basis. Analysts predict that Supernus Pharmaceuticals will post 1.87 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Glenmede Trust Co. NA increased its position in shares of Supernus Pharmaceuticals by 3.2% during the second quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock worth $39,070,000 after buying an additional 20,012 shares during the period. Janney Montgomery Scott LLC increased its position in shares of Supernus Pharmaceuticals by 28.1% during the third quarter. Janney Montgomery Scott LLC now owns 13,860 shares of the specialty pharmaceutical company’s stock worth $698,000 after buying an additional 3,039 shares during the period. Icon Advisers Inc. Co. acquired a new stake in shares of Supernus Pharmaceuticals during the third quarter worth $3,877,000. Oppenheimer Asset Management Inc. increased its position in shares of Supernus Pharmaceuticals by 9.2% during the third quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock worth $746,000 after buying an additional 1,251 shares during the period. Finally, Cynosure Advisors LLC increased its position in shares of Supernus Pharmaceuticals by 55.0% during the second quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock worth $494,000 after buying an additional 2,930 shares during the period. Institutional investors own 97.52% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Story: What kind of dividend yield to CEF’s pay?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.